Parathormone concentration in the fluid of fine-needle parathyroid biopsy for assessing the effectiveness of surgical treatment of patients with primary hyperparathyroidism

Abstract

changed parathyroid gland. The lack of localization of the parathyroid gland responsible for the symptoms of the disease in preoperative imaging tests translates into difficulties with intraoperative identification, which may influence the effectiveness of surgical treatment [3].The aim of the study is to assess the usefulness of intraoperative determination of PTH concentration in the fluid of fine-needle biopsy pathologically changed parathyroid glands for their identification and for evaluation of the effectiveness of surgical PHP treatment. The method we propose may complement the commonly used determination of PTH in peripheral blood serum.

Fine‐needle aspiration diagnosis of secondary malignant tumors of the thyroid gland: A single‐institution experience of 17 cases

“…In the present study, 1.3% of thyroid malignancies were secondary tumors, which is within the range of incidence rate reported in other series (0.06%–7.5%) 17–19,22–25 . The male‐to‐female ratio was 1:1.2, with slightly more females than males, similar to that reported in previous studies 17–19 .…”

“…To date (June 2023), there are only very few articles discussing FNA in SMTG, and most of them are just case reports. A search in Pubmed found only 9 studies on SMTG containing at least 8 cases with the following keywords (FNA biopsy, metastatic, thyroid, and secondary) 17–25 . In contrast, the number of cases included in our study was higher and the clinical information and IHC‐related data were more comprehensive.…”

“…A search in Pubmed found only 9 studies on SMTG containing at least 8 cases with the following keywords (FNA biopsy, metastatic, thyroid, and secondary). [17][18][19][20][21][22][23][24][25] In contrast, the number of cases included in our study was higher and the clinical information and IHC-related data were more comprehensive.…”

“…In the present study, 1.3% of thyroid malignancies were secondary tumors, which is within the range of incidence rate reported in other series (0.06%-7.5%). [17][18][19][22][23][24][25] The male-to-female ratio was 1:1.2, 18 This is the largest similar series reported in recent years. In contrast to previous studies, renal clear cell carcinoma with metastasis to the thyroid gland, which has been reported more frequently before, 4,8,17,23,25 was not found in our study, and it also did not include any sarcoma, which may be a bias caused by our sample size.…”

“…20,29 Metastatic renal carcinomas were the most common pitfall in previous series. 18,22 Smears of metastatic breast and renal carcinomas usually show mild and moderate cellular atypia; therefore, previous studies have suggested that metastases of renal and breast adenocarcinomas were almost indistinguishable from follicular tumor and PTC on cytologic grounds. 25 Therefore, a strict grasp of the nuclear diagnostic criteria of PTC can help to reduce the chances of misdiagnosing low-grade metastatic adenocarcinoma as PTC.…”